• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

FDA IDE validation of multiple myeloma MRD test by flow cytometry.

作者信息

Jevremovic Dragan, Shi Min, Horna Pedro, Otteson Gregory E, Timm Michael M, Bennett Shannon A, Baughn Linda B, Greipp Patricia T, Gonsalves Wilson I, Kapoor Prashant, Gertz Morie A, Binder Moritz, Buadi Francis K, Dispenzieri Angela, Kourelis Taxiarchis, Muchtar Eli, Zhou Jiehao, Rajkumar S Vincent, Kumar Shaji K, Olteanu Horatiu

机构信息

Division of Hematopathology, Mayo Clinic, Rochester, Minnesota, USA.

Quality Unit, Mayo Clinic, Rochester, Minnesota, USA.

出版信息

Am J Hematol. 2024 Dec;99(12):2399-2401. doi: 10.1002/ajh.27484. Epub 2024 Sep 18.

DOI:10.1002/ajh.27484
PMID:39291868
Abstract
摘要

相似文献

1
FDA IDE validation of multiple myeloma MRD test by flow cytometry.美国食品药品监督管理局（FDA）对通过流式细胞术进行的多发性骨髓瘤微小残留病（MRD）检测的研究性器械豁免（IDE）验证。
Am J Hematol. 2024 Dec;99(12):2399-2401. doi: 10.1002/ajh.27484. Epub 2024 Sep 18.
2
Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: An Economic Analysis.儿童急性淋巴细胞白血病微小残留病评估：一项经济学分析。
Ont Health Technol Assess Ser. 2016 Mar 8;16(8):1-83. eCollection 2016.
3
Clinical value of minimal residual disease assessed by multiparameter flow cytometry in amyloid light chain amyloidosis.多参数流式细胞术评估淀粉样轻链淀粉样变性微小残留病的临床价值
J Cancer Res Clin Oncol. 2022 Apr;148(4):913-919. doi: 10.1007/s00432-021-03653-z. Epub 2021 May 8.
4
Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection.用于急性髓系白血病微小/可测量残留病检测的12色流式细胞术检测方法的验证
Cytometry B Clin Cytom. 2023 Sep;104(5):356-366. doi: 10.1002/cyto.b.22140. Epub 2023 Aug 22.
5
Validation of a modified pre-lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B-non Hodgkin lymphoma.验证改良的裂解前样本制备技术在多发性骨髓瘤、慢性淋巴细胞白血病和 B 细胞非霍奇金淋巴瘤的流式细胞术微小残留病评估中的应用。
Cytometry B Clin Cytom. 2020 Sep;98(5):385-398. doi: 10.1002/cyto.b.21893. Epub 2020 Jun 12.
6
Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma.通过流式细胞术评估多发性骨髓瘤微小残留病的临床工作流程标准化。
Clin Lymphoma Myeloma Leuk. 2023 Jan;23(1):e41-e50. doi: 10.1016/j.clml.2022.10.008. Epub 2022 Oct 22.
7
Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy.使用共同抗体组合和分析策略对多发性骨髓瘤进行跨平台流式细胞术微小残留病评估的比较。
Cytometry B Clin Cytom. 2015 Mar;88(2):101-9. doi: 10.1002/cyto.b.21200. Epub 2014 Nov 17.
8
Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.多参数流式细胞术评估多发性骨髓瘤微小残留病
Klin Onkol. 2017 Summer;30(Supplementum2):21-28. doi: 10.14735/amko20172S21.
9
Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis.采用高敏流式细胞术评估多发性骨髓瘤可测量残留病灶：数据分析的国际协调方法。
Cytometry B Clin Cytom. 2022 Mar;102(2):88-106. doi: 10.1002/cyto.b.22053. Epub 2022 Jan 10.
10
Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma.多发性骨髓瘤微小残留病流式细胞术检测的监管视角
Cytometry B Clin Cytom. 2016 Jan;90(1):73-80. doi: 10.1002/cyto.b.21268. Epub 2015 Jul 25.

引用本文的文献

1
Measurable Residual Disease Analysis by Flow Cytometry: Assay Validation and Characterization of 385 Consecutive Cases of Acute Myeloid Leukemia.流式细胞术检测可测量残留病：385例急性髓系白血病连续病例的检测验证与特征分析
Cancers (Basel). 2025 Mar 29;17(7):1155. doi: 10.3390/cancers17071155.
2
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma.多发性骨髓瘤临床管理中微小残留病评估的机遇与挑战
Nat Rev Clin Oncol. 2025 Apr 7. doi: 10.1038/s41571-025-01017-x.
3
The prognostic impact of 1q21 gain/amplification in newly diagnosed multiple myeloma: a retrospective study based on a single center in China.
1q21 获得/扩增在新诊断多发性骨髓瘤中的预后影响：一项基于中国单中心的回顾性研究。
Ann Hematol. 2025 Jan;104(1):503-513. doi: 10.1007/s00277-024-06164-2. Epub 2025 Jan 4.